Entheon Biomedical Corp.

As of May 31, 2025, Entheon Biomedical Corp. has 13.86M shares outstanding.

These figures are as of May 31, 2025.

As of May 31, 2025, Entheon Biomedical Corp. maintains a current ratio of 27.75, meaning it holds 27.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended May 31, 2025. Return on assets (ROA) is negative at -96.92, reflecting losses generated across the asset base.

These figures cover the twelve months ended May 31, 2025. Free cash flow yield is negative at -30.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -39.25, meaning Entheon Biomedical Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Entheon Biomedical Corp.'s most recent stock split took place on March 1, 2024 with a 10:1 split ratio.

As of May 31, 2025, Entheon Biomedical Corp. has an Altman Z-Score of -18.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.